The U.S. Food and Drug Administration (FDA) has cleared the marketing of Global Kinetics Corporation‘s Personal KinetiGraph (PKG) technology designed to improve the assessment and monitoring of symptoms of Parkinson’s disease and other neurological disorders that affect movement. The Personal KinetiGraph offers automated reporting of a Parkinson’s patient’s movements so that neurologists and other physicians can more easily identify changes in symptoms to assist in decisions to optimize therapy.
“Monitoring changes in a patient’s movement symptoms is a critical element in the treatment of Parkinson’s and many other movement disorders, but it can be difficult for both patients and healthcare providers to identify and assess changes in movement symptoms effectively,” said Andrew Maxwell, managing director and CEO of Global Kinetics Corporation. “The Personal KinetiGraph provides clinicians with a clear and accurate assessment of the patient experience outside of office visits and examinations.”
The Personal KinetiGraph is a wrist-worn device that automatically records motion data over a period of up to ten days.The Personal KinetiGraph is a wrist-worn device that automatically records motion data over a period of up to ten days. The physician then receives detailed information about the patient’s mobility, identifying changes and trends that can be important considerations in the diagnosis and treatment of Parkinson’s disease. The device can also alert patients when it is time to take medication as prescribed and track when medication is taken to help improve treatment compliance.
At the moment, most physicians rely on clinical evaluation, a patient’s self-reporting of symptoms and response to medication to guide therapy. The Personal KinetiGraph was developed in response to this lack of objective measurement tools for movement disorders symptoms.